Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Recurrence 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × paclitaxel-Angiopep-2 conjugate × Clear all
NCT00539383 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Angiochem Inc

Phase 1 Completed
56 enrolled
BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡